Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Unusual Cutaneous Manifestations in a Patient with a History of Hepatitis B: A Case of Scleromyxedema and Literature Review.
Clin Cosmet Investig Dermatol
January 2025
Department of Dermatology, Guangzhou Dermatology Hospital, Guangzhou, Guangdong, People's Republic of China.
Scleromyxedema (SM) is a rare primary cutaneous mucinosis characterized by systemic papules and scleroderma-like manifestations, often associated with monoclonal gammopathy. We present the case of a 37-year-old male with SM who developed yellowish plaques on the neck and back over three years. Histopathological examination revealed mucin deposition, fibroblast proliferation, and fibrosis, supporting the diagnosis.
View Article and Find Full Text PDFErlotinib-induced Perioral Lesions Resembling Scleroderma.
Acta Dermatovenerol Croat
November 2024
Constantin A. Dasanu MD, PhD, Lucy Curci Cancer Center, Eisenhower Health, 39000 Bob Hope Dr, Rancho Mirage, CA 92270 , USA;
Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is currently used in the therapy of several solid malignancies. This agent has been associated with several dermatological side-effects, the most common being papulo-pustular acneiform rash. Herein we describe a unique skin effect in a patient treated with erlotinib for non-small cell lung cancer.
View Article and Find Full Text PDFChemotherapy-Induced Cutaneous Sclerosis: A Rare Clinical Finding.
Cureus
September 2024
Dermatology, University Hospital of Coimbra, Coimbra, PRT.
Scleroderma-like cutaneous sclerosis has been reported as a rare adverse reaction to several drugs, including the chemotherapeutical agent paclitaxel, used in therapeutic regimens for several malignancies. The sclerosis is usually limited to the skin, most commonly presenting in the lower limbs after weeks to months of therapy but is often refractory to treatment and progresses even after discontinuation of the offending agents, with significant resulting morbidity. We report a rare case of severe cutaneous sclerosis secondary to chemotherapy with nab-paclitaxel and gemcitabine, which did not respond to treatment and led to discontinuation of chemotherapy.
View Article and Find Full Text PDFAnesthetic management of a patient with mandibular hypoplasia, deafness, progeroid features, lipodystrophy syndrome: a case report.
JA Clin Rep
October 2024
Department of Anesthesiology, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-8-15 Kuramoto-Cho, Tokushima-Shi, Tokushima, 770-8503, Japan.
Background: Mandibular hypoplasia, deafness, progeroid features, and lipodystrophy (MDPL) syndrome is a rare autosomal dominant disorder that presents unique challenges for anesthetic management due to its multisystemic manifestations. This report outlines the anesthetic considerations for MDPL patients based on our case experience.
Case Presentation: A 15-year-old male with MDPL syndrome underwent testicular extraction under general anesthesia.
Phenotypical and biochemical characterization of murine psoriasiform and fibrotic skin disease models in Stabilin-deficient mice.
FEBS Open Bio
September 2024
Department of Dermatology, Venereology, and Allergology, University Medical Center and Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Stabilin-1 (Stab1) and Stabilin-2 (Stab2) are scavenger receptors expressed by liver sinusoidal endothelial cells (LSECs). The Stabilin-mediated scavenging function is responsible for regulating the molecular composition of circulating blood in mammals. Stab1 and Stab2 have been shown to influence fibrosis in liver and kidneys and to modulate inflammation in atherosclerosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!